SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.23) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.23), Zacks reports. SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. The business had revenue of $17.73 million during the quarter, compared to the consensus estimate of $17.71 million. SOPHiA GENETICS updated its FY 2025 guidance to EPS.
SOPHiA GENETICS Stock Up 0.3 %
SOPH stock opened at $3.11 on Thursday. SOPHiA GENETICS has a 52 week low of $2.70 and a 52 week high of $6.28. The company has a quick ratio of 3.59, a current ratio of 3.80 and a debt-to-equity ratio of 0.12. The firm has a 50-day simple moving average of $3.58 and a 200-day simple moving average of $3.56. The stock has a market capitalization of $203.32 million, a P/E ratio of -2.85 and a beta of 1.03.
Wall Street Analysts Forecast Growth
Separately, Craig Hallum started coverage on SOPHiA GENETICS in a report on Wednesday, December 18th. They issued a “buy” rating and a $11.00 price target for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, SOPHiA GENETICS currently has an average rating of “Moderate Buy” and a consensus price target of $7.40.
About SOPHiA GENETICS
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.
Further Reading
- Five stocks we like better than SOPHiA GENETICS
- What Are Dividend Champions? How to Invest in the Champions
- Robinhood’s Rally: Is Global Expansion the Next Big Catalyst?
- Best Aerospace Stocks Investing
- Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors
- Investing In Preferred Stock vs. Common Stock
- Why Now Might Be the Best Time to Buy Target Stock
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
